Received date: November 17, 2017; Accepted date: November 30, 2017; Published date: December 05, 2017
Citation: Chhabra S, Singh A (2017) Dangers to Mothers and Babies in Early Onset Hypertensive Disorders. J Women’s Health Reprod Med. Vol.1 No.1:5
Objective: To know the present status of etiology, pathology and outcome in women with EO and LO HDsP.
Current status-etiopathogy: Women with LO HDsP are believed to be related to maternal constitution. EO HDsP probably has placental origin with interplay between maternal constitution, placental factors, and inappropriate adaptive changes in pregnancy, predominantly involving cardiovascular and inflammatory system. EO are believed to be associated with increased arterial stiffness that extends beyond pregnancy, leading to adverse vascular outcomes, not so in LO HDsP. Studies are being done about relationship to genetic variations, immune system and association between hCG and a variety of thrombophilia disorders.
Feto-maternal outcome: When HDsP are diagnosed before 34 weeks, mothers and clinicians are faced with difficult decision of early delivery of extremely premature infant, with slim chance of survival, may be with major neurological dysfunction, more so when the baby is immature or continue with pregnancy with major risks to mother and even baby, especially in low resource settings. Conservative management may improve fetal outcome, but maternal mortality, morbidity even intra uterine death are real concerns. Most of EO cases present with severe rapidly progressive disease with significantly higher risk of obstetric interventions, with dangers to mother, baby. However LO HDsP can also become dangerous for the mother as well as baby.
Prevention: Role of aspirin, calcium has been documented in prevention of LO HDsP but continues to be surrounded by controversies. Not much is known about the role in relation to differences in EO or LO HDsP. Studies are also being done about supplementation with vitamins C and E. Some have shown benefits, others not so. Low-molecular-weight heparin has also been studied with no effect in onset of EO or severe pre-eclampsia.
Conclusion: There are controversies about many issues about EO/LO cases of HDsP. A lot of research is needed about their etiology, pathology, management, outcome and prevention.
Early onset; Late onset; Hypertensive disorders; Effects; Mother; Baby
Concept of early onset (EO), late onset (LO) hypertensive disorders of pregnancy (HDsP), as two different forms is being accepted as they seem to have different etiologists, pathogenesis and effects on mother and baby. However there are commonalities and a lot is still not known and research continues. Hypertensive disorders of pregnancy (HDsP) continue to be among the most significant, intriguing, and unsolved problems in obstetrics. Some women develop hypertension during pregnancy much earlier, some late and have variations in the effects also [1-6]. HDsP are angiogenic disorders, probably originating in very early pregnancy  and are clinically visible late in pregnancy. Research continues. Though the importance of gestation at obvious hypertension was reported many years back, as many cases were reported with poor perinatal outcome with early onset (EO) HDsP  this has been relooked with division of HDsP into EO, as de novo hypertension with or without proteinuria before 34 weeks gestation and late onset, (LO) at completed and after 34 weeks [9-11]. Efforts are being made to elucidate differences in the causes, pathology and outcome of EO and LO HDsP [12-17]. EO and LO HDsP are believed to be different disease entities with overlapping clinical signs. Researchers believe that EO HDsP, with the potential for more serious adverse outcomes for the mother and the baby, should be regarded as different form of HDsP from LO HDsP.
Literature search was done by various search engines like PubMed, Google, Up-to-date, and other search engines to look at studies, reviews, short commentaries to get the desired information as per the objectives and personal experience was added. There were no criteria whatever literature relevant to the objective was available was looked into. Objective to know the present status of knowledge of pathology, etiology and outcome in EO and LO HDsP.
Current status of division, incidence, etiopathology and feto maternal outcome
The concept of EO and LO HDsP is relatively new. It is being widely accepted that these two entities have different etiologies and should be regarded as different forms of the HDsP [18-21]. However there is still inconsistency among the definitions of EO and LO disorders, where the dividing line varies about gestational age between 28 to 37 weeks [22,23]. Earlier divided HDsP, as preterm (before 37 weeks) and term (completed 37 weeks or more). Because of controversies in the definition of EO and LO disorders, International Society for the Study of Hypertension in Pregnancy  had a group of researchers for general agreement and 73.0% suggested to deÃ¯Â¬Âne EO HDsP before 3 4weeks of pregnancy, 18.0% suggested 32 weeks and 9.0% suggested 28 weeks. So now a case is considered EO. If HDsP occur before 34 weeks and LO if it occurs > 34 weeks.
EO HDsP comprise, a small subset of cases of HDsP (5% to 20%), depending on the studies, but are the most severe form of HDsP  have reported the overall preeclampsia rate 3.1%, increasing incidence with gestation, EO and LO preeclampsia, 0.38% and 2.72% respectively. Earlier  reported a ratio of 32% in the second trimester, 32% between 28 to 36 weeks, and 36% between 37 to 40 weeks  reported the ratio of second trimester HDsP 15.3%, [28,29] 24.51% and reported 23.4%. Similarly the study  reported a gradual increase with gestation, ratio of 9.40% before 28 weeks, 19.61% between 28-31 weeks, 13.33% between 32-33 weeks, and 57.66% ≥ 34 weeks of gestation. [30,31] reported only 6.3% cases as EOHDsP. Reported cases of as early as 4th month of pregnancy 3.9%, 26.8% in 8th month and 24.7% in 9th month of pregnancy. Though this is not part of this review if one goes with the standard definition, hypertension (blood pressure of 140 mm of Hg or more systolic and 90 mm of Hg or more diastolic) before 20 weeks is considered essential hypertension and not gestational hypertension. However preeclampsia can be superimposed on essential hypertension.
The first to report the differences between pathogenesis of EO and LO HDsP . In EO, the physiological changes were found to be restricted to the decidual segment alone, absent throughout the entire length of spiral arteries, seen in basal plates of placenta with a defect in the normal interaction between migratory trophoblastic and maternal uterine tissues . After doing review of the literature about epidemiology and pathology supported the hypothesis that preeclampsia was the result of heterogeneous causes [3,17] also reported that, unlike EO preeclampsia, which involved severe placental pathology, LO preeclampsia with intact placenta and maternal cardiovascular deregulation may be prevented with a lifestyle intervention, in particular, low intensity exercise  reported that the placenta of women with LO HDsP was similar to placenta of gestationalage- matched normal controls , reported that in cases of EO HDsP, endothelial damage was because of abnormal placentation, whereas in LO cases, endothelial damage has been linked to association of insulin resistance(IR). A stronger association with inadequate and incomplete spiral artery remodelling, visualized by alterations in uterine artery Doppler flow has been reported in EO cases, not in LO cases. EO HDsP have been found to be characterized by marked vascular, metabolic and inflammatory changes which were responsible for generalized endothelial dysfunction and end-organ damage due to vascular compromise  and hence were potentially life-threatening for the mother and the baby [3,12,28]. It is not certain whether EO HDsP have linkage with cardiovascular dysfunction and lifestyle modification  reported that trophoblastic invasion into the placental bed in EO preeclampsia (or) intrauterine growth restriction was limited by increased apoptosis, resulting in narrower spiral arteries  reported that chorionic villous vascularization was diminished in cases of EO HDsP, which lead to more of small for gestational age (SGA) babies . And also reported placental hypoplasia significantly associated with histological evidence of placental vascular lesions with the disorder in the early third trimester and concluded that the placenta of women with EO HDsP were significantly different from LO cases [39,40]. Also reported that, for most of the cases of EO HDsP, the root cause was the placentation and placental abnormalities. Reported relatively reduced placental perfusion which leads to inflammation, oxidative stress, and endoplasmic reticulum stress, which converged to modify maternal physiology, endothelium being an important target. Redman and colleagues  also reported that EO HDsP were caused by endovascular trophoblastic remodelling, Madazli et al.  reported that the magnitude of defective trophoblastic invasion of the spiral arteries correlated with the severity of the disorder . Reported that EO, but not LO HDsP were associated with increased arterial stiffness that extended beyond pregnancy and later contributed to adverse vascular outcome, Yinon et al.  reported that women with a history of EO preeclampsia or intrauterine growth restriction without preeclampsia exhibited impaired vascular function, which might explain their predisposition to placental disease and their higher risk of future vascular disease . Reported that in cases of EOHDsP, placental growth factor was lower and soluble fms like tyrosine kinase-1 and vascular cell adhesion molecule-1 higher than in controls. In LO HDsP, the patients with abnormal uterine artery Doppler indices had higher soluble fms-like tyrosine kinase-1 and vascular cell adhesion molecule-1 levels [40,44,45]. Reported changes of the blood flow within the placental bed spiral arteries and in the uterine arteries at different gestations. In EOHDsP, notches and other changes like increased pulsatility index [PI] of the uterine Doppler waveforms were detected and these women with a persistent abnormal mean PI represented the group with the greatest risk for adverse perinatal outcome. Blair et al. . reported that EO preeclampsia was a severe form of pre-eclampsia that was associated with altered physiological characteristics and gene expression in the placenta. This case control study focused on DNA methylation and gene expression of whole chorionic villi samples from 20 EO HDsP placentas and 20 gestational age matched controls from preterm births and reported that there were wide spread DNA methylation alterations in EOHDsP but not in LO HDsP, which might have been associated with changes in placental function. Masuyama et al.  reported the blood levels of adipocytokines differing with a significant elevation of lepton in both subtypes, relative to controls but adiponectin was increased only in LOHDsP. Significant differences in angiogenic factors and adiponectin were found between normal and overweight women only in LOHDsP. Rolfo et al.  reported that disruption of oxygen sensing in EO HDsP vs. LO HDsP and control placentae, was the first molecular evidence of the existence of two distinct preeclampsia diseases and the unique molecular O2 sensing signature of EO-PE placentae may be of diagnostic value when assessing high risk pregnancies and their severity. Probably high levels of interleukin-6 and fibrinogen were associated with a history of EOHDsP . Examined whether allelic variants of the innate immune receptors, Toll-like receptor 4 (TLR4) and nucleotide-binding oligomerization domain 2 (NOD2), (that impair the inflammatory response to endotoxin), were related to preeclampsia and haemolysis, elevated liver enzymes and low platelets (HELLP) syndrome and reported an association of common TLR4 and NOD2 gene variants, and pro-inflammatory phenotype with history of EO preeclampsia and HELLP syndrome. Researchers also determined five common mutations in TLR4 (D299G and T399I) and NOD2 (R702W, G908R and L1007fs) in 340 primiparous women with a history of EO preeclampsia, of whom 177 (51%) women had developed HELLP syndrome and 113 women with a history of uneventful pregnancies worked as controls. In addition, researchers assessed plasma levels of pro inflammatory biomarkers C-reactive protein, interleukin-6, soluble intercellular adhesion molecule-1, fibrinogen and von Will ebr factor in a subset of 214 women followed for at least six months after delivery. After adjustment for maternal age and chronic hypertension, attenuating allelic variants of TLR4 were found to be more common in women with a history of EO than in controls (or 2.9 [95% CI 1.2-6.7]). According to genetic factors accounted for more than half the incidence of preeclampsia and maternal genes contributed more than fetal genes, and a couple effect occurred because of the interaction between genes of the mother and the father. Cnattingius et al. and Kovo et al. [50,51] reported that the EO HDsP had higher rates of FGR with lesions of maternal vascular supply compared]. The researchers also concluded that the placental/fetal vascular supply in combination with maternal vascular lesions were more dominant in EO disorders with FGR, compared with EOHDsP without FGR.
Park et al in their study of Australian population for prediction of HDsP have reported that a variety of demographic factors, mean maternal arterial blood pressure (MAP), uterine artery pulsatility index (UtA PI) and pregnancy associated plasma protein A (PAPP-A) could predict EO pre-eclampsia in 95% of women with 10% false-positive rate .
When pre-eclampsia is diagnosed before 34 weeks, clinicians and mothers are faced with difficult decision of either early delivery of an extremely premature infant with a slim chance of survival and major neurological handicap or continue the pregnancy with risk to the woman’s health. Most of the EO cases have been reported to be associated with FGR [9,20,21,44,45]. An important cause of preterm birth and adverse maternal and neonatal outcome [28,59] reported larger impact on the foetus and the neonate in EO cases due to more chances of prematurity and immaturity. Paruk et al., Hall et al., Ganzevoort et al. and Ebeigbe et al. [53-57] reported that EOHDsP, by virtue of their unpredictable nature and prediction for multi-organ involvement were associated with substantial maternal and fetal morbidity and mortality. Zhnag et al. and Irgens et al. [57,58] reported unfavourable long-term maternal consequences for women with a history of EO disorder. Sezik et al. and Gasem et al. [59,60] reported 8% to 22% HELLP/ELLP in EO disorders, maybe because more cases were managed conservatively for longer duration. Researchers  reported renal failure in 13%, placental abruption in 15%, preterm preeclampsia cases and concluded that a conservative approach to the management of EOHDsP resulted in a good obstetric outcome for the majority of foetuses, but this needed to be balanced against the significant risk of increase in morbidity to the mother. Also, reported a twofold increase in maternal mortality and a significantly increased incidence of renal failure and HELLP syndrome in EO cases. The perinatal mortality was fourfold in the EO cases compared to the LO cases, principally due to prematurity and FGR. Bombrys  reported that with expectant management, 36% patients of EO HDsP (at ≤ 32 weeks) had pulmonary edema or haemolytic anaemia. The researchers concluded that there was significant maternal morbidity at ≥ 32 weeks with minimal neonatal benefits and so, early intervention following corticosteroid administration was needed. However, in countries with low resources for neonatal care of very LBW babies, perinatal loss is high, so a balance is essential in a retrospective study of 264 singleton pregnancies with LO HDsP reported that 57.6% were severe and median gestational age at diagnosis was 37 (34-43) weeks, 30.7% of patients experienced ≥ 1 major maternal complication and also 34 (12.9%) cases of eclampsia and there were 5 intrauterine deaths, all due to placental abruption. The researchers concluded that LO disorders were also not innocuous.
In their studies reported the mean gestational age at delivery in EOHDsP 29 weeks and in LO disorders 37 weeks [62,63]. The researchers concluded that most of the EO cases who presented with severe and rapidly progressive disease were associated with significantly higher risk of obstetric interventions and poorer perinatal outcome, than LOHDP. In a population-based retrospective cohort study, Chang et al.  reported that despite a second normotensive pregnancy, women with EO disease in their first pregnancy had greater odds of SGA infants, preterm births, fetal deaths, CS and placental abruption in the second pregnancy, compared to women with LO after controlling for confounders reported cesarean section rate of 58.7% in EOHDsP and significant maternal morbidity. Researchers reported that 84.8% patients of EOHDsP had preterm births. The disease was severe at presentation or rapidly progressive leading to delivery within 72 hours of presentation  Ebeigbe et al. reported 19.4% preterm births in cases who had hypertensive disorders at 4th month of pregnancy which dropped to 4% at 9th month [55-58]. In their prospective study reported that a mean of 11 days were gained by expectant management in EOHDsP. The perinatal mortality rate was 24 with a neonatal survival rate of 94%. In a larger retrospective study of 49,812 women, reported that of second trimester HDsP cases, there were 16.9% intrauterine deaths and 12% neonatal deaths. Irgens et al.  also reported unfavorable neonatal outcome in women with EOHDsP have reported mean gain of 8.8 ± 1.5 (range 1-19 weeks) weeks in gestational age in the early onset cases Ganzevoort et al.  reported that adverse neonatal outcome in EO HDsP was predominantly influenced by gestational age but in the study by Sezik et al.  conservative management was associated with 94.5% IUDs. The researchers concluded that in low-resource settings, expectant management of EO HDsP was associated with relatively higher rates of perinatal mortality and should be limited to gestational ages between 28 and 34 weeks of gestation . In their study reported the mean birth weight in EOHDsP 998 ± 323 gms and in LO disorders 2345 ± 479 gms. In their retrospective analysis of outcome in patients with severe preeclampsia, Bombrys et al.  reported the birth weights of 27% babies <10% for gestational age, and 8% <5% at 27 to 33 weeks of gestation [62,63].
Prediction of early and late-onset HDsP
Various demographic and other factors have been studied for prediction of EO and LO HDsP, Crispi et al.  reported the mean age of women who had EOHDsP 29 ± 5 and LO disorder 32 ± 5 years. However, Valensise et al.  reported a mean age of 32 ± 4 years in EO and 34 ± 4 years in LO category. Although an age more than 35 year is linked to a higher risk for preeclampsia, the importance of age in EO and LO has not been studied well. In a retrospective  Kennethe et al. reported 56.8% primigravida with LO diseases, Crispi e al.  reported 83% primigravida in EO category and 41% in LO, Akolekar et al.  reported nulliparous women 58% in EO and 64.2% in LO cases. More research is essential, Kaaja et al.  reported that LOHDsP had increased IR, which persisted for around 3 months after pregnancy. Wolf and colleagues  reported that the women who had increased IR in the first trimester, were at an increased risk of subsequent preeclampsia in last few weeks (LO) of pregnancy, with the mean gestational age at delivery of 37.6 ± 3 weeks  evaluated the first trimester plasma adiponectin mean concentrations in EO HDsP and found a significant difference in adiponectin plasma values only between women in the LO pre-eclampsia group versus those in the control group. First trimester mean homeostasis model assessment ratio values, were significantly higher in the preeclampsia group than that in the control group. In preeclampsia women with standard normal glucose tolerance, an increased IR was associated only with LOHDsP, Pilalis et al.  measured the uterine artery blood flow and reported that abnormal uterine Doppler at 11-14 weeks identified one-third of women who were likely to have EO severe pre-eclampsia [69,70] have also reported similar findings compared maternal cardiac function at 24 weeks gestation in a group of normotensive asymptomatic patients with subsequent development of EO and LO and supported the hypothesis of different hemodynamic and origins for EO HDsP  evaluated the soluble fms-like tyrosine kinase-1 (sFlt-1), placental growth factor (PlGF), and sFlt-1 / PlGF ratio for the prediction of EO and LO disorders in a high-risk cohort and reported that serum PlGF concentrations were lower in women who developed disorders early, compared to those who developed LO disorders.
Prevention and new research
A study and reported that supplementation with 2 gms of Calcium per day decreased the incidence of HDsP, however information was limited about EO/LO cases [72,73] suggested that in persons with low-calcium diets who were at high risk of hypertensive disorders, calcium supplementation could prevent the development of HDsP but not much was reported about difference between EO and LO. Role of calcium needs more studies. A Meta-analysis of many trials suggested that administration of low dose aspirin at or before the 16th week of pregnancy was associated with a small but significant reduction in the risk for preeclampsia and preterm births. This finding also differed significantly from the later than 16 weeks group. However there is not much information about differences between EO and LO HDsP, Schiff et al. [74,75] reported that daily low dose of aspirin taken during the third trimester of pregnancy significantly reduced the incidence of HDsP in women at high risk for these disorders, possibly through the correction of an imbalance between levels of thromboxane and prostacyclin, but did not comment about EO and LO  reported that low dose aspirin and antioxidants may have beneficial effect in the prevention of HDsP in the high risk primigravida subjects, by restoring prostacyclin/thromboxane imbalance, previously suggested as an important aetiological factor in gestational hypertension and preeclampsia but not about relation with EO and LO. Some others have also reported similar findings [77,78]. Study revealed that there were significant differences in fetal and neonatal growth between EO and LO preeclampsia and the catch up for growth might have started during neonatal period. Studies are being done about the association between a variety of thrombophilia disorders and EO pre-eclampsia [79,80]. Some of these disorders, such as hyperhomocysteinaemia, can easily be corrected from the metabolic point of view [81-83], but currently it is unknown whether or not metabolic correction translated into improved perinatal outcome, Chappell et al.  reported the beneficial effects of vitamin C and E on markers of oxidative stress, endothelial activation, and the frequency of EO pre-eclampsia. However studies have shown no reduction in the rates of either serious adverse outcomes of pregnancy associated hypertension or preeclampsia among low risk, nulliparous women. The findings of several studies provided no support for the use of vitamin C and E supplementation in pregnancy to reduce the risk of preeclampsia or its complications . Research continues. From meta-analysis of individual patients, Carbillon et al.  reported that low-molecular-weight heparin did not reduce the composite outcome of EO or severe pre -eclampsia, birth of small for gestational age neonates, fetal loss, or placental abruption and in subgroup analyses, did not reduce the risk of EO pre-eclampsia.
Those women who had EOHDsP had higher risk of developing cardiovascular morbidity at middle age. Irgens et al.  did a large follow-up study and provided evidence of increased risk of dying because of cardiovascular disease after EO and a lower risk after LO preeclampsia. This raised the question whether this effect was secondary to the acquired metabolic syndrome during pregnancy in these women or to an inherited accelerated aging of the cardiovascular system [86-89]. Earlier studied 125 women with severe preeclampsia in the second trimester with follow-up for an average of 5.4 years and reported increased risk for repeat preeclampsia, particularly the second trimester cases. They were at higher risk of morbidity and mortality in subsequent pregnancies also and chronic hypertension. Others also reported that women who get EO HDsP have more chances of recurrence in future pregnancy with risk for a variety of cardiovascular disorders (CVD) like stroke, coronary artery disease, heart failure, and peripheral vascular disease . Researchers reported differences in the prevalence of common modifiable CVD risk factors postpartum and suggested that prevention strategies should be stratified according to severity and gestational age at onset of the HDsP [90,91].
EO and LO HDsP seem to be disorders with different etiology, different pathology different feta maternal outcome and different squeal, with some commonalities in all the aspects. There are dangerous outcomes in both, but more serious in EO. Both continue to create serious problems for mother and baby. A lot of more research is needed.